On Monday, H.C. Wainwright maintained a Neutral rating on shares of Rapt Therapeutics (NASDAQ: RAPT) following the company's third-quarter financial report. Rapt Therapeutics posted a net loss of $0.47 per share for the third quarter of 2024, which was notably better than the analyst's projection of a net loss of $0.63 per share.
The company's research and development (R&D) expenses amounted to $13.3 million, and selling, general and administrative (SG&A) expenses were reported at $6.4 million. These figures contrasted with H.C. Wainwright's estimates of $22.0 million for R&D and $4.0 million for SG&A.
The firm also adjusted its full-year 2024 net loss projection for Rapt Therapeutics to $2.56 per share, down from the previous estimate of $2.70 per share. By the end of the third quarter of 2024, Rapt Therapeutics had approximately $97.9 million in cash and cash equivalents. According to H.C. Wainwright, this capital is expected to fund the company's operations through the middle of 2025.
Despite the better-than-expected quarterly performance and the reduced net loss forecast for the full year, H.C. Wainwright pointed out concerns regarding the future of Rapt Therapeutics.
The termination of the zelnecirnon program has introduced uncertainty about the potential value inflection points that could be realized within the current operational runway. The analyst's commentary emphasized this uncertainty and the decision to maintain a Neutral rating on the stock without setting a price target.
In other recent news, RAPT Therapeutics (NASDAQ:RAPT) has undergone significant changes in its operations and financial outlook. The company recently announced the discontinuation of its drug, Zelnecirnon, following feedback from the FDA. This has led to a shift in focus towards the development of next-generation CCR4 antagonists, with a lead candidate expected to be nominated in the first half of 2025.
In response to these developments, Leerink Partners maintained its Market Perform rating and $2.00 price target for RAPT, while Stifel downgraded RAPT Therapeutics from Buy to Hold and reduced its price target to $2.00. Concurrently, JPMorgan (NYSE:JPM) also downgraded the company's stock from Neutral to Underweight, highlighting a lack of near-term value-creating catalysts.
RAPT Therapeutics reported a net loss of $0.71 per share for the second quarter of 2024, slightly better than the expected $0.72 per share. The company's research and development expenses were $22.6 million, and its selling, general, and administrative expenses were $6.7 million, both figures coming in under estimates.
In a strategic move, RAPT Therapeutics has implemented a repricing of certain stock options to incentivize staff without the need for additional equity grants or increased cash compensation.
The repricing affects options with exercise prices above $8.00 per share, including those held by key executives. The new exercise price has been set at $1.57 per share, contingent upon employees and consultants remaining with the company through a specified retention period.
InvestingPro Insights
Recent data from InvestingPro provides additional context to Rapt Therapeutics' financial situation. The company's market capitalization stands at $37.75 million, reflecting its current valuation in the market. InvestingPro Tips highlight that RAPT holds more cash than debt on its balance sheet, which aligns with the article's mention of $97.9 million in cash and cash equivalents. This cash position is crucial, as another tip indicates that the company is quickly burning through cash, a common characteristic of biotech firms in the research and development phase.
The company's financial challenges are further underscored by its negative operating income of $114.85 million over the last twelve months as of Q3 2024. This figure correlates with the article's discussion of ongoing losses and R&D expenses. Additionally, InvestingPro Tips note that analysts do not anticipate the company to be profitable this year, which is consistent with H.C. Wainwright's projections of continued net losses.
The stock's performance has been notably poor, with InvestingPro data showing a 42.86% decline in the past month and a staggering 95.65% drop year-to-date. This downward trend aligns with the uncertainty surrounding the company's future value inflection points mentioned in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 8 additional tips for RAPT, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.